{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:32:59Z","timestamp":1793745179231,"version":"4.6.1"},"reference-count":50,"publisher":"BMJ","issue":"5","license":[{"start":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T00:00:00Z","timestamp":1748649600000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Science and Technology Innovation Action Plan of Shanghai","award":["No. 24J12800800"],"award-info":[{"award-number":["No. 24J12800800"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2025,5,4]]},"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The challenges that remain in the treatment of solid tumors with chimeric antigen receptor (CAR)-T cells include limited solid tumor-specific targets and poor CAR-T cell expansion and function due to limited availability of solid tumor antigens outside the tumor microenvironment. Prostate cancer is the second most common cancer among men worldwide. Current CAR-T therapies for prostate cancer lack specific targets, posing safety risks. To overcome these problems, we identified prostatic acid phosphatase (PAP, also known as ACPP or ACP3) as a feasible CAR-T target for prostate cancer and developed CoupledCAR, a novel approach for expanding tumor-targeting CAR-T cells without tumor antigens.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analyzed the expression of PAP from The Cancer Genome Atlas database and validated its expression in normal and cancer tissues through immunohistochemistry staining. To generate anti-PAP specific antibodies, we screened the human single-chain antibody library using transmembrane PAP-His antigen and selected antibodies based on their binding ability and specificity. We constructed PAP-targeted CAR and evaluated their antitumor efficacy both in vitro and in vivo. We validated the function of PAP CoupledCAR in both in vitro and in vivo experiments, and further analyzed its mechanism using single-cell RNA sequencing (scRNA-Seq).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PAP was specifically expressed in prostate epithelial and prostate cancer cells, with no expression in other tissues. Seven single-chain variable fragments were screened from the human single-chain antibody library, with S5D1 showing the highest binding ability for the PAP. PAP CAR-T cells demonstrated strong antitumor efficacy both in vitro and in vivo. Furthermore, the CoupledCAR system significantly expanded PAP CAR-T cells, promoting memory-like status, reducing exhaustion, and enhancing their antitumor efficacy. The scRNA-Seq demonstrated that the expansion of PAP CAR-T cells in the CoupledCAR system is mediated by costimulatory signals and cytokine signals, rather than T-cell receptor signals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study is the first to demonstrate that PAP is a specific target for CAR-T therapy in prostate cancer, both in vitro and in vivo. We developed the CoupledCAR platform technology for solid tumor CAR-T cell therapy, enabling the expansion of tumor-targeting CAR-T cells without requiring tumor antigens and thereby enhancing their functionality against solid tumors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2024-011238","type":"journal-article","created":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T09:15:14Z","timestamp":1748682914000},"page":"e011238","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach"],"prefix":"10.1136","volume":"13","author":[{"given":"Zhiyuan","family":"Cao","sequence":"first","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengfei","family":"Pu","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianyang","family":"Jiang","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiting","family":"Han","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaogang","family":"Shen","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wensheng","family":"Wang","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ding","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhipeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Huang","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Jia","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor X","family":"Lu","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Tian","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Wu","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Xiao","sequence":"additional","affiliation":[{"name":"Innovative Cellular Therapeutics Holdings Limited, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,31]]},"reference":[{"key":"2025100313414427000_13.5.e011238.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"2025100313414427000_13.5.e011238.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"2025100313414427000_13.5.e011238.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"2025100313414427000_13.5.e011238.4","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaw2293","article-title":"Supercharging adoptive T cell therapy to overcome solid tumor-induced immunosuppression","volume":"11","author":"Mardiana","year":"2019","journal-title":"Sci Transl Med"},{"key":"2025100313414427000_13.5.e011238.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"2025100313414427000_13.5.e011238.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"2025100313414427000_13.5.e011238.7","first-page":"7","article-title":"Cancer Statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA A Cancer J Clinicians"},{"key":"2025100313414427000_13.5.e011238.8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01726-1"},{"key":"2025100313414427000_13.5.e011238.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2013.09.003"},{"key":"2025100313414427000_13.5.e011238.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2016.06.010"},{"key":"2025100313414427000_13.5.e011238.11","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910828","article-title":"Improving CAR T-cell persistence","volume":"22","author":"Pietrobon","year":"2021","journal-title":"Int J Mol Sci"},{"key":"2025100313414427000_13.5.e011238.12","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abn3353","article-title":"B cell targeting in CAR T cell therapy: Side effect or driver of CAR T cell function?","volume":"14","author":"Chen","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100313414427000_13.5.e011238.13","doi-asserted-by":"publisher","DOI":"10.1126\/science.aav8692"},{"key":"2025100313414427000_13.5.e011238.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.aay5967"},{"key":"2025100313414427000_13.5.e011238.15","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01740","article-title":"Car T cells in solid tumors: blueprints for building effective therapies","volume":"9","author":"Knochelmann","year":"2018","journal-title":"Front Immunol"},{"key":"2025100313414427000_13.5.e011238.16","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1001\/jamaoncol.2024.3891","article-title":"Chimeric antigen receptor t cells targeting cd19 and gcc in metastatic colorectal cancer: a nonrandomized clinical trial","volume":"10","author":"Chen","year":"2024","journal-title":"JAMA Oncol"},{"key":"2025100313414427000_13.5.e011238.17","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/icb.1991.58","article-title":"Preparation and characterization of a chimeric CD19 monoclonal antibody","volume":"69 (Pt 6)","author":"Zola","year":"1991","journal-title":"Immunol Cell Biol"},{"key":"2025100313414427000_13.5.e011238.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci Rep"},{"key":"2025100313414427000_13.5.e011238.19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109.098301"},{"key":"2025100313414427000_13.5.e011238.20","first-page":"1723","article-title":"Acid phosphatase as tumor marker of prostatic cancer","volume":"82","author":"Saito","year":"1991","journal-title":"Nihon Hinyokika Gakkai Zasshi"},{"key":"2025100313414427000_13.5.e011238.21","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.10.5939"},{"key":"2025100313414427000_13.5.e011238.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-1651"},{"key":"2025100313414427000_13.5.e011238.23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0073072","article-title":"Transmembrane prostatic acid phosphatase (TMPAP) interacts with snapin and deficient mice develop prostate adenocarcinoma","volume":"8","author":"Quintero","year":"2013","journal-title":"PLoS One"},{"key":"2025100313414427000_13.5.e011238.24","doi-asserted-by":"crossref","first-page":"171","DOI":"10.14348\/molcells.2015.2272","article-title":"Screening and characterization of a novel RNA aptamer that specifically binds to human prostatic acid phosphatase and human prostate cancer cells","volume":"38","author":"Kong","year":"2015","journal-title":"Mol Cells"},{"key":"2025100313414427000_13.5.e011238.25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13578-015-0033-y","article-title":"Cellular prostatic acid phosphatase (cPAcP) serves as a useful biomarker of histone deacetylase (HDAC) inhibitors in prostate cancer cell growth suppression","volume":"5","author":"Chou","year":"2015","journal-title":"Cell Biosci"},{"key":"2025100313414427000_13.5.e011238.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107419"},{"key":"2025100313414427000_13.5.e011238.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.015"},{"key":"2025100313414427000_13.5.e011238.28","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.4143\/crt.2017.473","article-title":"Delayed terminal ileal perforation in a relapsed\/refractory b-cell lymphoma patient with rapid remission following chimeric antigen receptor t-cell therapy","volume":"50","author":"Hu","year":"2018","journal-title":"Cancer Res Treat"},{"key":"2025100313414427000_13.5.e011238.29","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/bjh.14923","article-title":"Donor-derived CD19-targeted T cell infusion induces minimal residual disease-negative remission in relapsed B-cell acute lymphoblastic leukaemia with no response to donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation","volume":"179","author":"Chen","year":"2017","journal-title":"Br J Haematol"},{"key":"2025100313414427000_13.5.e011238.30","doi-asserted-by":"publisher","DOI":"10.1038\/nri3405"},{"key":"2025100313414427000_13.5.e011238.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2010.02.013"},{"key":"2025100313414427000_13.5.e011238.32","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4478"},{"key":"2025100313414427000_13.5.e011238.33","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.249"},{"key":"2025100313414427000_13.5.e011238.34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1084\/jem.174.3.547","article-title":"Characterization of antigen-specific CD4+ effector T cells in vivo: immunization results in a transient population of MEL-14-, CD45RB- helper cells that secretes interleukin 2 (IL-2), IL-3, IL-4, and interferon gamma","volume":"174","author":"Bradley","year":"1991","journal-title":"J Exp Med"},{"key":"2025100313414427000_13.5.e011238.35","doi-asserted-by":"publisher","DOI":"10.1084\/jem.180.3.1159"},{"key":"2025100313414427000_13.5.e011238.36","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-15-1498"},{"key":"2025100313414427000_13.5.e011238.37","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.12.7417"},{"key":"2025100313414427000_13.5.e011238.38","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1610544113"},{"key":"2025100313414427000_13.5.e011238.39","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba1786","article-title":"Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling","volume":"372","author":"Weber","year":"2021","journal-title":"Science"},{"key":"2025100313414427000_13.5.e011238.40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002555","article-title":"Understanding T cell phenotype for the design of effective chimeric antigen receptor T cell therapies","volume":"9","author":"Tantalo","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100313414427000_13.5.e011238.41","doi-asserted-by":"publisher","DOI":"10.1136\/gut.50.2.150"},{"key":"2025100313414427000_13.5.e011238.42","doi-asserted-by":"publisher","DOI":"10.1038\/nri3442"},{"key":"2025100313414427000_13.5.e011238.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-21246-9","article-title":"Inference and analysis of cell-cell communication using CellChat","volume":"12","author":"Jin","year":"2021","journal-title":"Nat Commun"},{"key":"2025100313414427000_13.5.e011238.44","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954936","article-title":"Role of B cells as antigen presenting cells","volume":"13","author":"Rastogi","year":"2022","journal-title":"Front Immunol"},{"key":"2025100313414427000_13.5.e011238.45","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"2025100313414427000_13.5.e011238.46","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-021-01084-0","article-title":"Prostate Cancer Immunotherapy-Finally in From the Cold?","volume":"23","author":"Runcie","year":"2021","journal-title":"Curr Oncol Rep"},{"key":"2025100313414427000_13.5.e011238.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2005.05.021"},{"key":"2025100313414427000_13.5.e011238.48","doi-asserted-by":"crossref","first-page":"893","DOI":"10.5858\/arpa.2016-0119-RA","article-title":"Diagnostic immunohistochemistry: what can go wrong and how to prevent it","volume":"140","author":"Gown","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"2025100313414427000_13.5.e011238.49","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01504-7","article-title":"Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy","volume":"16","author":"Bulliard","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025100313414427000_13.5.e011238.50","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12939"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-011238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T20:41:57Z","timestamp":1759524117000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-011238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":50,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,31]]},"published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1136\/jitc-2024-011238"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-011238","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]}}}